Vancouver, B.C. – December 9th, 2022 – Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, announced today that its Board of Directors (the “Board”) has initiated a review process to consider, review and evaluate strategic alternatives for the Company.
While the Board continues to support Origin as a psychedelics industry focused investment issuer, given the current state of the industry and the capital markets generally, the Board considers it appropriate to consider strategic alternatives that are in the best interests of the Company.
The Board’s strategic review process will encompass an evaluation of the Company’s current strategic direction, operations, market valuation and capital structure and will consider appropriate alternatives for the Company which may include one or more of the following: continuation as a standalone public company, strategic investor investment, acquisition by or a merger with an industry partner that may involve all or part of our business or assets and any other strategic alternatives that may be identified during our strategic review.
Other than as described in this news release, the Company has not made any decisions related to strategic alternatives at this time and there can be no assurance that the evaluation of strategic alternatives will result in any transaction proceeding or change in strategy. The Company does not intend to comment further unless and until further disclosure is appropriate or necessary.
About Origin Therapeutics
Origin Therapeutics is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector.
Learn more at www.originpsychedelics.com and follow the Company on LinkedIn, Twitter, and Instagram
For Further Information:
Alexander Somjen
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc
www.originpsychedelics.com
info@originpsychedelics.com
Forward-Looking Information and Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature, including but not limited to the considerations and outcomes of the strategic review. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including but not limited to adverse market conditions and risks inherent in the Company’s business in general. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this press release. Except as required by applicable law, the Company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.